QUICK ANSWER · AEO / GEO
An endogenous mitochondrial-derived peptide studied mainly in mechanistic and preclinical research, without established therapeutic efficacy.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- human bioavailability, half-life, tissue distribution and blood-brain exposure after administration
- safe exposure range and short- or long-term adverse effects
- whether endogenous Humanin measurements are analytically comparable across assays
- whether observational longevity associations are causal
- clinical relevance of cell and rodent neuroprotection findings
- current product-specific regulatory and anti-doping status across jurisdictions
What limits these conclusions?
- The human literature mainly measures endogenous Humanin and often uses small exercise cohorts or observational associations. Preclinical studies use heterogeneous sequences, analogues, routes and models. HNG results cannot be assigned to native Humanin, and human-derived cells or ex-vivo sperm are not human administration evidence. Assay specificity may also be complicated by Humanin-like sequences.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
- https://www.accessdata.fda.gov/scripts/cder/daf/
- https://precision.fda.gov/uniisearch/srs/unii/H975EUX36G
- https://www.ema.europa.eu/en/medicines
- https://precision.fda.gov/ginas/app/ui/substances/625c3f53-6384-46c7-9421-0a03aba06a64
- https://pubmed.ncbi.nlm.nih.gov/11717357/
- https://pubmed.ncbi.nlm.nih.gov/27923980/
- https://pubmed.ncbi.nlm.nih.gov/32271093/
- https://pubmed.ncbi.nlm.nih.gov/34351816/
- https://pubmed.ncbi.nlm.nih.gov/23836030/
- https://pubmed.ncbi.nlm.nih.gov/32575074/
- https://pubmed.ncbi.nlm.nih.gov/30959025/
- https://clinicaltrials.gov/study/NCT04449419
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is Humanin?
Humanin is described pharmacologically as Endogenous mitochondrial-derived peptide; synthetic Humanin and HNG analogues are experimental. An endogenous mitochondrial-derived peptide studied mainly in mechanistic and preclinical research, without established therapeutic efficacy.
Does Humanin have strong evidence?
PrimeCoreBio records Evidence Grade D. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Humanin approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.